Jupiter Topco LLC Takes Position in Oruka Therapeutics, Inc. $ORKA

Key Points

• Jupiter Topco LLC acquired 1.38 million Oruka Therapeutics shares worth approximately $131 million, giving it a 2.08% stake. Institutional investors collectively own 56.44% of the company.
• Analyst sentiment remains broadly positive: 10 analysts rate ORKA a Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $134.30.
• ORKA shares opened at $99.44 after declining 2.3%, while the company reported a quarterly loss of $0.55 per share—$0.04 worse than expectations. Insiders have sold 83,116 shares worth $6.64 million over the past 90 days.

Jupiter Topco LLC bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,375,844 shares of the company's stock, valued at approximately $130,968,000. Jupiter Topco LLC owned about 2.08% of Oruka Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Sei Investments Co. lifted its position in Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company's stock valued at $1,120,000 after purchasing an additional 13,164 shares during the last quarter. Moody Aldrich Partners LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth $3,844,000. Handelsbanken Fonder AB bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $15,313,000. Dimensional Fund Advisors LP bought a new stake in shares of Oruka Therapeutics in the 1st quarter worth about $5,543,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Oruka Therapeutics by 18.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company's stock valued at $3,559,000 after buying an additional 11,205 shares in the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on ORKA shares. Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. HC Wainwright restated a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. UBS Group lifted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Finally, BTIG Research reissued a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.30.

Insiders Place Their Bets

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the sale, the insider directly owned 32,718 shares of the company's stock, valued at $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 83,116 shares of company stock worth $6,636,533. Corporate insiders own 23.49% of the company's stock.

Oruka Therapeutics Trading Down 2.3%

ORKA stock opened at $99.44 on Thursday. Oruka Therapeutics, Inc. has a 12 month low of $14.61 and a 12 month high of $115.51. The company has a 50-day moving average price of $93.74 and a 200 day moving average price of $66.89. The stock has a market cap of $6.58 billion, a PE ratio of -48.99 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source